The Expression of Cancer-testis Antigen in Ovarian Cancer and the Development of Immunotherapy

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 Mar 9

PMID 35261795

Authors

Jianhang Zhao

Zhaoxu Xu

Yan Liu

Xiaobin Wang

Xinli Liu

Yanan Gao

Ying Jin

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is a relatively common tumor in women with the highest mortality among female reproductive system tumors. The lack of apparent early symptoms and effective screening strategies often leads to ovarian cancer being diagnosed at an advanced stage. Immunotherapy relying on tumor-associated antigens might improve the treatment of ovarian cancer. Cancer-testis antigens (CTAs) are ideal tumor-associated antigens, and MAGE-A, NY-ESO-1, CT45, and Sp17 are classic CTAs highly expressed in ovarian cancer. Here, we review the research on CTAs in ovarian cancer, including prognostic value and advances in immunotherapy, all of which are essential for developing a theoretical basis for targeted therapy strategies.

Citing Articles

Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact.

Imani S, Tagit O, Pichon C NPJ Vaccines. 2024; 9(1):14.

PMID: 38238340 PMC: 10796345. DOI: 10.1038/s41541-024-00807-1.

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.

Alsalloum A, Shevchenko J, Fisher M, Philippova J, Perik-Zavodskii R, Perik-Zavodskaia O Int J Mol Sci. 2023; 24(20).

PMID: 37894816 PMC: 10606439. DOI: 10.3390/ijms242015134.

Characterization of Cancer/Testis Antigens as Prognostic Markers of Ovarian Cancer.

Vlasenkova R, Konysheva D, Nurgalieva A, Kiyamova R Diagnostics (Basel). 2023; 13(19).

PMID: 37835834 PMC: 10572515. DOI: 10.3390/diagnostics13193092.

MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy.

Lisica Sikic N, Petric Mise B, Tomic S, Spagnol G, Matak L, Juretic A Cancers (Basel). 2023; 15(19).

PMID: 37835391 PMC: 10571787. DOI: 10.3390/cancers15194697.

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.

Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X Mol Cancer. 2023; 22(1):141.

PMID: 37649123 PMC: 10466891. DOI: 10.1186/s12943-023-01844-5.

References

Kanduc D . Oligopeptides for Immunotherapy Approaches in Ovarian Cancer Treatment. Curr Drug Discov Technol. 2018; 16(3):285-289. DOI: 10.2174/1570163815666180525071740. View

Kranz L, Diken M, Haas H, Kreiter S, Loquai C, Reuter K . Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534(7607):396-401. DOI: 10.1038/nature18300. View

Li Z, Li W, Meklat F, Wang Z, Zhang J, Zhang Y . A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies. Int J Cancer. 2007; 121(7):1507-11. DOI: 10.1002/ijc.22842. View

Gure A, Chua R, Williamson B, Gonen M, Ferrera C, Gnjatic S . Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005; 11(22):8055-62. DOI: 10.1158/1078-0432.CCR-05-1203. View

Esfandiary A, Ghafouri-Fard S . MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015; 7(6):683-704. DOI: 10.2217/imt.15.29. View

Yamasaki N, Richardson R, ORand M . Expression of the rabbit sperm protein Sp17 in COS cells and interaction of recombinant Sp17 with the rabbit zona pellucida. Mol Reprod Dev. 1995; 40(1):48-55. DOI: 10.1002/mrd.1080400107. View

Ayyoub M, Memeo L, Alvarez-Fernandez E, Colarossi C, Costanzo R, Aiello E . Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS. Cancer Immunol Res. 2014; 2(10):943-8. DOI: 10.1158/2326-6066.CIR-13-0211. View

Grob J, Mortier L, DHondt L, Grange F, Baurain J, Dreno B . Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017; 2(5):e000203. PMC: 5687540. DOI: 10.1136/esmoopen-2017-000203. View

Wen Y, Richardson R, Widgren E, ORand M . Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 2001; 357(Pt 1):25-31. PMC: 1221924. DOI: 10.1042/0264-6021:3570025. View

10.

Straughn Jr J, Shaw D, Guerrero A, Bhoola S, Racelis A, Wang Z . Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer. 2004; 108(6):805-11. DOI: 10.1002/ijc.11617. View

11.

Chen Y, Hsu M, Lee P, Shin S, Mhawech-Fauceglia P, Odunsi K . Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer. 2009; 124(12):2893-8. DOI: 10.1002/ijc.24296. View

12.

Schutt C, Mirandola L, Figueroa J, Nguyen D, Cordero J, Bumm K . The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma. Oncotarget. 2017; 8(59):100280-100287. PMC: 5725019. DOI: 10.18632/oncotarget.22213. View

13.

Schuler P, Harasymczuk M, Visus C, DeLeo A, Trivedi S, Lei Y . Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014; 20(9):2433-44. PMC: 4017234. DOI: 10.1158/1078-0432.CCR-13-2617. View

14.

Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H . Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstet (Sunnyvale). 2014; Suppl 4:3. PMC: 3899646. DOI: 10.4172/2161-0932.S4-003. View

15.

Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O . Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 2013; 11(1):41. PMC: 3689639. DOI: 10.1186/1478-811X-11-41. View

16.

Zhang S, Zhou X, Yu H, Yu Y . Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010; 10:163. PMC: 2868811. DOI: 10.1186/1471-2407-10-163. View

17.

Gordeeva O . Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. Semin Cancer Biol. 2018; 53:75-89. DOI: 10.1016/j.semcancer.2018.08.006. View

18.

Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T . Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer. 1995; 64(6):388-93. DOI: 10.1002/ijc.2910640607. View

19.

Bonehill A, Van Nuffel A, Corthals J, Tuyaerts S, Heirman C, Francois V . Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res. 2009; 15(10):3366-75. DOI: 10.1158/1078-0432.CCR-08-2982. View

20.

Richardson R, Yamasaki N, ORand M . Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction. Dev Biol. 1994; 165(2):688-701. DOI: 10.1006/dbio.1994.1285. View